Change in Cerebral Blood Flow after Palliative Percutaneous Angioplasty and Timing of Second Stage Carotid Artery Stenting in Staged Angioplasty

Hisashi NAGASHIMA,1 Kazuhiro HONGO,2 and Alhusain NAGM2,3

1Clinical Safety and Quality Management Section, University of Toyama Hospital, Toyama, Toyama, Japan; 2Department of Neurosurgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan; 3Department of Neurosurgery, Al-Azhar University Faculty of Medicine-Nasr city, Cairo, Egypt

Abstract

The purpose of this study is to elucidate the hemodynamic changes after palliative angioplasty and the timing of second stage carotid artery stenting (CAS) in staged angioplasty for patients with severe hemodynamically compromised carotid artery stenosis. Among consecutive 111 patients with carotid artery stenosis, chronological changes in the cerebral blood flow of all 11 hemodynamically compromised patients treated with CAS were evaluated with single photon emission computed tomogram (SPECT) in each stage of the treatment. Ten of these 11 patients underwent staged angioplasty and one was treated with single-stage CAS. All the 10 patients who underwent staged angioplasty showed improved cerebral vascular reactivity (CVR) on SPECT after the first stage palliative angioplasty. Only one patient treated with staged angioplasty with 4-week interval before the CAS showed restenosis of the lesion. Cerebral hyperperfusion syndrome (CHS) was not observed in nine of 10 patients with staged angioplasty. One patient of staged angioplasty (who presented restenosis at the time of elective CAS) and another patient in whom we could not apply staged angioplasty (for his renal dysfunction) showed CHS after CAS. In conclusion, restoration of CVR could be achieved within a few days following palliative angioplasty, and 1–2-week interval is enough for staged angioplasty.

Key words: carotid artery, stent, staged angioplasty, cerebral blood flow, cerebral hyperperfusion

Introduction

Intracranial hemorrhage due to cerebral hyperperfusion syndrome (CHS) is known as a catastrophic complication following carotid artery revascularization.1,2 Poor cerebral vascular reactivity (CVR) delivered from long-standing cerebral blood flow (CBF) impairment caused by severe carotid artery stenosis is regarded as a risk factor.3 Staged angioplasty, which allows CBF improvement with minimal and palliative percutaneous angioplasty followed by curative carotid artery stenting (CAS) with a 1–2-month interval, is recently introduced as an effective procedure to prevent CHS after CAS.4,5 However, the effect of palliative angioplasty in severe hemodynamically-compromised patients and the ideal period before CAS were not elucidated. We investigated the chronological changes in CBF following the staged angioplasty and evaluated the efficacy of staged angioplasty.

Materials and Methods

A total of 111 patients with carotid artery stenosis were treated at our institute (Shinshu University Hospital, Nagano, Japan) between May 2010 and April 2014. Cerebral blood flow and CVR were evaluated with quantitative analysis of single photon emission computed tomogram (SPECT) with acetazolamide challenge in the patients with stenosis over 80% on North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria, lesions over 250 cm/sec peak systolic velocity on carotid Doppler ultrasonography or findings of reduced signal in distal internal carotid or intracranial vessels on

Received February 1, 2018; Accepted March 30, 2018

Copyright® 2018 by The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives International License.
magnetic resonance angiography. Hemodynamic compromise was estimated with existence of stage-2 areas proposed by Japanese Extracranial–Intracranial Bypass Trial (JET)-2 Study on “% Increase Map”. Among 111 patients, 13 patients with severe and widespread hemodynamic compromise on single photon emission computed tomogram were candidates for staged angioplasty. Two of the 13 patients were treated with carotid endarterectomy for severely calcified lesions, one patient with renal dysfunction was treated with single-stage carotid artery stenting for his renal dysfunction and 10 were treated with staged angioplasty.

CAS (due to the limitation of contrast medium) and the remaining 10 patients were treated with staged angioplasty (Fig. 1).

Staged angioplasty, elective CAS following minimal percutaneous balloon dilatation with a few weeks interval, was done according to the description by Yoshimura et al. We started the first-stage palliative angioplasty with 2.0-mm balloon and finished after achieving improvement of contrast run out of collapsed distal carotid artery without re-constriction of the lesion after 30-min observation on angiogram (Fig. 2). When the lesion showed re-constriction after angioplasty with 2.0-mm balloon, the size of balloon was stepwisely increased up to a maximum of 3.0-mm until achieving satisfactory result. If the lesion showed re-constriction with 3.0-mm balloon, longer time (30–60 sec) dilatation was repeated without further oversized-balloon.

Cerebral blood flow and CVR of all 11 patients were evaluated with serial SPECT with acetazolamide challenge before and after each stage of the treatment within a few days.
was obtained from all patients prior to the treatment. All patients were managed below 120 mmHg systolic blood pressure over a few days after each treatment and dual anti-platelet drugs (75 mg clopidogrel and 100 mg aspirin) were given during the course of treatment.

Results

Lesions of all 10 patients treated with staged angioplasty were successfully dilated and showed improved preexisting flow restriction after the first-stage angioplasty without evidence of acute thromboembolic complications, arterial dissections, or acute occlusions. None of the 10 patients treated with staged angioplasty showed CHS symptoms, and impaired vascular reactivity areas represented as stage-2 on SPECT were resolved within a few days after the first-stage angioplasty. During the course of treatment between the first-stage angioplasty and the second-stage CAS, none of the 10 patients showed neither clinical events nor radiological abnormalities on CT scan. The CAS was performed within 16–69 days after the first-stage angioplasty in the 10 patients. In one patient (Case 1), who was urgently treated for progressive and multiple infarctions, CAS was postponed to 69 days to avoid hemorrhagic complications. Another patient (Case 4) received CAS after 28-day interval, and remaining eight patients were treated within 16–23-day interval.

Single photon emission computed tomogram before the CAS was scheduled 1–3 days before the scheduled second-stage CAS. Nine of the 10 patients maintained recovered CVR at the time of CAS; however, one patient (Case 4) showed recurrence of hemodynamic compromise on SPECT. In this patient (Case 4), apparent restenosis was observed at the CAS and briefly showed talkative tendency suggesting of CHS after CAS. Remaining nine patients showed no symptoms suggesting CHS during the course of treatment. Severely decreased CBF and impaired vascular reactivity to acetazolamide challenge test improved without any neurological deficits after the CAS in all 10 patients (Table 1). Two of 10 patients showed progressive dilatation or ulcer formation at the lesion without additional neurological deficits or apparent radiological findings (on CT) in the course of treatment. One patient who could not receive staged angioplasty showed euphoric and talkative symptoms for a few days after the CAS and apparent CHS finding was observed on SPECT.

Discussion

Intracranial hemorrhage caused by CHS is known as a most catastrophic complication after carotid artery revascularization. It is regarded as the result of lost vascular reactivity due to long-standing CBF impairment. Mortality and morbidity rates may significantly increase in patients with intracranial hemorrhage after carotid revascularization, and strict control of post-operative blood pressure might reduce the risk of developing intracranial hemorrhage after CEA. CVR measurement on SPECT using acetazolamide challenge is regarded to be an effective measure to predict CHS after CEA, and numbers of alternative measures have been introduced.

Transluminal carotid artery angioplasty with stenting (initially introduced for surgically high-risk patients in endarterectomy) has been recently established as an effective measure for carotid

Table 1 Patients of carotid artery stenosis treated with staged angioplasty for severe and widespread hemodynamic compromise on SPECT

<table>
<thead>
<tr>
<th>No.</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Symptoms</th>
<th>Side</th>
<th>Treatment</th>
<th>Interval (days)</th>
<th>Re-stenosis after 1st PTA</th>
<th>Hyper-perfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>74</td>
<td>F</td>
<td>Impending stroke</td>
<td>R</td>
<td>staged CAS</td>
<td>69</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2.</td>
<td>74</td>
<td>M</td>
<td>Lt. visual loss/stroke</td>
<td>L</td>
<td>staged CAS</td>
<td>21</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3.</td>
<td>71</td>
<td>M</td>
<td>LOC attacks</td>
<td>R</td>
<td>staged CAS</td>
<td>23</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>4.</td>
<td>74</td>
<td>M</td>
<td>Stroke</td>
<td>R</td>
<td>staged CAS</td>
<td>28</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>5.</td>
<td>59</td>
<td>M</td>
<td>Amaurosis fugax</td>
<td>R</td>
<td>staged CAS</td>
<td>16</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6.</td>
<td>74</td>
<td>M</td>
<td>Amaurosis fugax</td>
<td>R</td>
<td>staged CAS</td>
<td>16</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7.</td>
<td>74</td>
<td>M</td>
<td>Stroke</td>
<td>R</td>
<td>staged CAS</td>
<td>19</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>8.</td>
<td>70</td>
<td>M</td>
<td>Stenosis progression</td>
<td>R</td>
<td>staged CAS</td>
<td>16</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>9.</td>
<td>70</td>
<td>M</td>
<td>Stroke</td>
<td>R</td>
<td>staged CAS</td>
<td>19</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>10.</td>
<td>79</td>
<td>M</td>
<td>Stroke</td>
<td>R</td>
<td>staged CAS</td>
<td>19</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

revascularization. On the other hand, CBF changes and catastrophic hemorrhagic complications following CAS have been reported. Besides, some reports showed the relationship between the pre-procedural CVR and post-procedural CHS. Dual antiplatelet therapy with aspirin and clopidogrel around CAS is an essential measure to avoid the thromboembolic complications after CAS. Ogasawara et al. reported their result of nationwide survey for carotid artery revascularization in Japan and concluded that strict control of post-operative blood pressure prevented intracranial hemorrhage in patients with CHS after CEA; however, no relationship between blood pressure and intracranial hemorrhage after CAS. In that study, 30 of 1596 patients (1.9%) after CEA and 31 of 2898 patients (1.1%) after CAS experienced CHS, respectively. Additionally, 6 (0.4%) after CEA and 21 (0.7%) after CAS experienced intracranial hemorrhage, respectively. Mortality and morbidity rates were higher in patients with intracranial hemorrhage. Accordingly, following CAS, the risk of CHS with blood pressure reduction is less possible to be reduced. In addition, strong antiplatelet therapy is an indispensable prerequisite for the patients treated with CAS, because they are at a higher risk for advancing hemorrhage. It is important to establish the effective measure to avoid CHS in CAS for patients with impaired vascular reactivity.

Staged angioplasty has initially been proposed in severe hemodynamically compromised patients by Yoshimura et al. to recover vascular reactivity with minimal percutaneous angioplasty followed by curative CAS with a few weeks interval. It is, however, currently introduced over 27% of neuroendovascular institutes in Japan as an effective measure to prevent CHS after CAS. In our case series, 11 of 111 consecutive patients with carotid artery stenosis and CVR impairment, 10 cases were successfully treated with staged angioplasty.

Uchida et al. reported their 43-case series and successfully treated with staged angioplasty in 39 patients with successfully improving cerebrovascular reactivity before the second-stage CAS. However, immediate stent placement was required (due to inadequate dilatation in three and vascular dissection in one) during the first-stage angioplasty and hyperperfusion was observed after the first-stage angioplasty in four patients. In our case series, staged angioplasty could not be applied in one patient due to renal dysfunction (induced by repeated treatment for contralateral carotid artery stenosis) and coronary artery insufficiency (Fig. 1). In this patient, symptomatic CHS was observed with remarkable hyperperfusion on SPECT. In staged angioplasty, avoiding over dilatation or immediate stent placement is an important matter to avoid CHS.

We made the first-stage palliative angioplasty with minimal sized balloon with a great care not to over-dilate the lesion to avoid stent placement due to vascular dissection. Despite the lesion not being obviously dilated, restoration of impaired CVR was observed within a few days (Fig. 4). In the first-stage palliative angioplasty, improving of the preexisting flow restriction might be enough to restore the impaired CVR.

In our case series, interval of the two treatments was ranged 16–69 days. In a case of 74-year-old woman with stroke-in-progress (Case 1), we need a 2-month interval with apprehension of hemorrhagic sequelae for apparent and wide spread stroke. In other nine patients, interval until second-stage CAS was within 3 weeks in eight and 4 weeks in one, respectively. The patient with a 4-week interval after the first-stage angioplasty (Case 4) showed restoration of the lesion at the second-stage CAS.
and mild hyperperfusion syndrome was observed after CAS. In staged angioplasty, balloon angioplasty without obvious dilation is enough for restoring the impaired CVR, but is highly possible to result in restenosis. According to our case series, while CVR recovered within a few days after the first-stage angioplasty, at least 1-week interval between the two treatments is enough and should be accomplished within 3 weeks. In cases with severe hemodynamic compromise and acute stage ischemic lesions, staged angioplasty will be effective for reducing the risk of hemorrhagic complications; however, it is still difficult to define the exact interval between the two procedures. Further investigations might be needed.

This study has limitations that the results are based on a small case series in one institute. As a further problem, pathological conditions, such as acute thromboembolic occlusions are possible to appear additionally. As the staged angioplasty is anticipated as an effective measure to avoid CHS after CAS, establishing the standardized method is indispensable. Furthermore, as the indication of SPECT with acetazolamide challenge is quite limited for its risk of acute pulmonary edema as a side effect, the criteria for indicating the staged angioplasty without evaluating CVR by SPECT with acetazolamide challenge is also important. From the result of nationwide survey by Hayakawa et al., staged angioplasty is already introduced in over 27% of neuroendovascular institutes in Japan, detailed investigation and analysis with a large number of patients is necessary. Moreover, despite having effective role to prevent CHS, the staged angioplasty requires two procedures, which doubles the risk and cost. Improvident application of staged angioplasty is not only unnecessary but also harmful for patients and wasteful from the medico-economical perspective. Strict-and-wise decision for indicating staged angioplasty based on detailed CVR investigation is mandatory.

Conclusion

Staged angioplasty for severe carotid artery stenosis with hemodynamic compromise is a safe and effective procedure to avoid the catastrophic CHS complications. However, staged angioplasty increases risks and costs following the procedure and should be applied under strict indications.

Conflicts of Interest Disclosure

Authors have no conflicts of interest with regard to submit the manuscript and authors who are member of the Japan Neurosurgical Society (HN, KH, and AN) completed the registration of online Self-reported COI Disclosure Statement Forums through the website for the Japan Neurosurgical Society.

References


Address reprint requests to: Hisashi Nagashima, MD, 2630 Sugitani, Toyama, Toyama 930-0194, Japan. e-mail: hinagashima-nsu@umin.ac.jp